股票研究 /[Table_Date] 2025.07.08 股东结构优化顺利，龙头经营稳步向上 美丽田园医疗健康(2373) 6935023 | 风险提示：客流低于预期、生美-医美导流不及预期、行业竞争恶化。 | | --- | | [Table_Finance] 财务摘要（百万人民币） | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | --- | --- | | 营业收入 | 1780.74 | 1635.41 | 2145.07 | 2572.20 | 3076.26 | 3313.03 | 3590.85 | | (+/-)% | 18.5 | -8.2 | 31.2 | 19.9 | 19.6 | 7.7 | 8.4 | | 毛利润 | 833.79 | 717.84 | 977.10 | 1190.00 | 1444.49 | 1557.17 | 1701.49 | | 净利润 | 193.48 | 103.11 | 215.66 | 228.46 | 307.65 ...

机构：东方财富证券 研究员：刘嘉仁 2025 年3 月公司提出资本市场价值提升计划：1）提高分红比例：确立长期股东回报机制，2025-2027 年除特殊情况外拟将年度归母净利润不低于50%用于分红。2）股东结构优化：持续吸引优质长线机构 投资者，着力提升市场流动性和交易活跃度。3）长效激励机制：实施核心管理层股权激励计划，考核 指标同时涵盖2025-2027 年营业收入及利润提升的双重维度。 在股东结构优化方面，截止2025 年6 月25 日，CPE 已达成一系列相关协议或完成相关交易，拟出售其 持有的约0.51 亿股（占比约21.77%），该系列交易的投资者包括外资长线医疗健康领域基金、科技创 新战略投资基金、国际领先的长线基金、国际优质对冲基金等，在完成该系列交易后，CPE 将不再作 为公司主要股东。 筹码面来看，CPE 退出并引入长线投资人帮助公司进一步推进资本市场价值提升计划。CPE 作为陪伴 公司多年、持股比例较高的重要一级投资人股东，其减持需求一定程度对公司股价向上趋势带来压力， 本次CPE 顺利退出后，一方面减持压力消除，此外长线资金进入也侧面证明其对于公司长期发展具备 良好信心，引入对冲基金为 ...

2025 年 07 月 07 日 晨会纪要 研究所： 证券分析师： 余春生 S0350513090001 yucs@ghzq.com.cn [Table_Title] 晨会纪要 ——2025 年第 113 期 观点精粹: 最新报告摘要 2025 年 6 月重卡销量同比显著增长，看好全年重卡内需景气度--行业动态研究 股市行情上涨，后续转债如何选择？--固定收益点评 全球领先玩具制造商，印尼新厂于年中投产--德林国际/文娱用品(01126/213605) 点评报告（港股美股） 医药行业深度报告：数说日本医疗的现代化历程，质量、效率和成本的特有平衡--产业 PPT 报告（无评级） 黄金价格波动的底层逻辑--宏观专题研究 谷歌与 CFS 签订 200MW 核聚变供电协议，产业长期发展趋势已立--事件点评 湖北省人形机器人产业投资母基金设立，步科发布第四代无框力矩电机及中空驱动器--行业周报 工信部召开光伏企业座谈会，海风政策催化不断落地--行业周报 红利资产从共识到分化的再审视--资产配置报告 光刻机行业深度报告（一）：核心部件篇，曙光已现--行业 PPT 报告 人形机器人灵巧手深度报告：灵巧手赛道蓝海可期，各类新 ...

Company Overview - The original major shareholder CPE has reached a series of agreements to sell approximately 51.329 million shares, representing 21.77% of the company's total issued shares (excluding treasury shares), and will no longer be a major shareholder after the completion of this series of transactions [1][2] - The investors involved in this transaction include foreign long-term healthcare funds, strategic investment funds for technological innovation, leading international long-term funds, and high-quality international hedge funds [1] Comments on Shareholder Structure - The exit of CPE and the introduction of international long-term capital are expected to optimize the shareholder structure and improve market liquidity [2] - The entry of high-quality international investors is anticipated to bring rich industry resources and an international perspective, injecting new momentum into the company's business expansion and innovation [2] Business Performance - For the period from January to May 2025, the company reported a more than 20% year-on-year increase in both equity consumption and net consumption [2] - By business segment, the beauty and wellness sector grew by over 20%, medical beauty increased by 10%, and sub-health medical services surged by over 50% [2] - The integration of the acquired company Nairui is progressing smoothly, which is expected to enhance operational efficiency and improve profit margins [2] Growth Strategy - The company is focusing on a "dual beauty + dual wellness" model for synergistic development, with a positive outlook on growth driven by both internal and external factors [2] - Internally, the company is optimizing single-store operational efficiency and increasing the penetration rate of value-added services [2] - Externally, the successful integration of Nairui is expected to continue expanding membership assets and national layout through acquisitions [2] Management Incentives and Profit Distribution - The company has introduced equity incentives for the management team, with performance targets covering revenue and profit for the next three years [3] - A long-term shareholder return mechanism has been established, with plans to allocate no less than 50% of annual net profit attributable to shareholders for dividends from 2025 to 2027 [3] Profit Forecast and Valuation - The profit forecast for 2025-2026 remains unchanged, with the current stock price corresponding to a P/E ratio of 22x for 2025 and 20x for 2026 based on net profit excluding non-recurring items [3] - The target price has been raised by 68% to HKD 37, corresponding to a P/E ratio of 27x for 2025 and 24x for 2026, indicating a 22% upside potential [3]

Group 1 - CPE plans to sell approximately 51.32 million shares, representing 21.77% of the total share capital, and will no longer be the major shareholder after the transaction [1] - The entry of long-term quality funds is expected to stabilize and improve the company's shareholding structure, with new shareholders including foreign long-term healthcare funds and leading international hedge funds [1] - The company has successfully implemented key strategic measures, including optimizing the shareholder structure, maintaining high dividends (not less than 50% from 2025 to 2027), and continuing long-term incentive mechanisms [1] Group 2 - The company is expected to achieve a net profit of approximately 290 million in 2025, with a year-on-year growth rate of about 27%, corresponding to a valuation of 23x [2] - The integration of the Nairu brand is yielding continuous results, and the health business is experiencing explosive growth, effectively countering the pressure from the medical beauty sector [2] - The exit of CPE is seen as a factor that alleviates previous stock price pressures, contributing to a more favorable outlook for the company's performance [2]

Core Insights - The company has a competitive advantage due to high-quality membership and comprehensive lifecycle management, with traditional beauty services as the foundation and medical beauty and sub-health services extending customer lifecycles, leading to high customer retention [1] - The company is focusing on increasing dividend ratios, optimizing shareholder structure, and implementing long-term incentive mechanisms, which may enhance liquidity and indicate potential for PE valuation recovery [1] - The company has raised its target price and maintains a buy rating [1] Business Performance - In 2024, the beauty and health service revenue reached 1.443 billion, a year-on-year increase of 20.9%, with organic growth of 6%. By the end of 2024, the number of direct and franchise stores reached 239 and 276, respectively, with net new openings of 68 and 77 stores during the year [1] - The company plans to further acquire 20% of Guangzhou Nairui's shares, increasing its stake to 90%, and is expected to continue industry consolidation and business acquisitions to enhance market share and scale effects [1] Medical and Sub-health Services - In 2024, revenue from medical beauty and sub-health services reached 928 million and 201 million, respectively, with year-on-year growth of 9.1% and 98.9%. The penetration rate of beauty members into medical beauty and sub-health services reached 24.9% [2] - The women's special care center generated over 100 million in revenue, with a year-on-year increase of over 300%, accounting for more than 50% of sub-health medical business revenue, and active membership increased by 200% year-on-year [2] Strategic Initiatives - The company is implementing three strategic initiatives to maximize shareholder value: establishing a long-term shareholder return mechanism, attracting quality long-term institutional investors, and implementing a core management equity incentive plan [2] Profit Forecast and Valuation - The company forecasts net profits attributable to shareholders of 315 million, 368 million, and 418 million for 2025-2027, maintaining a strong cash position of nearly 1.4 billion by the end of 2024 [3] - The company is assigned a target price of 37.00 HKD for 2025, based on a 25x PE valuation, reflecting its position as a leading brand in beauty and health and its ongoing initiatives to enhance shareholder value [3]

证券研究报告 美丽田园医疗健康 (2373 HK) 内生扎实、外延提份额，上调目标价 华泰研究 更新报告 2025 年 6 月 27 日│中国香港 零售 三大战略举措释放股东价值 据公司官网 6 月 25 日披露，公司始终将股东价值最大化作为核心经营理念， 正布局三大战略举措：1）确立长期股东回报机制，2025-2027 年除特殊情 况外拟将年度归母净利润不低于 50%用于分红；2）持续吸引优质长线机构 投资者，构建更为健康多元的股东生态体系；3）实施核心管理层股权激励 计划，考核指标同时涵盖 2025-2027 年营业收入及利润提升的双重维度。 盈利预测与估值 我们预计 25-27 年归母净利润分别达 3.15/3.68/4.18 亿元（维持），公司账 面现金充沛（24 年底近 14 亿），主营业务发展稳健并持续内生外延提升份 额、亚健康管理业务快增。可比公司 25E 一致预测 PE 均值 17 倍，考虑公 司为美容与保健品牌龙头、正布局多举措提升股东价值，给予 25 年 25xPE， 目标价 37.00 HKD（汇率 0.91；前值 24.23HKD，对应 25 年 17 倍 PE）。 风险提示：会员向医 ...

行业估值方面，医疗保健设备和服务行业市盈率（TTM）平均值为-21.43倍，行业中值0.3倍。美丽田园 医疗健康市盈率17.18倍，行业排名第29位；其他巨星医疗控股（02393.HK）为0.23倍、京玖康疗 （00648.HK）为0.38倍、永胜医疗（01612.HK）为3.97倍、环球医疗（02666.HK）为4.67倍、瑞慈医疗 （01526.HK）为5.5倍。 资料显示，美丽田园医疗健康产业有限公司引进国际美容理念,并使用先进的护理技术、产品仪器、质 控流程、服务标准,为每位客人带来舒适的美容美体护理服务。 公司于1993 年建立旗舰品牌美丽田园,该品牌是中国美丽与健康管理服务行业中成立已久的国内连锁品 牌之一。公司还建立了三个新兴品牌,即贝黎诗、研源及秀可儿。截至2022年6月30日,公司整体服务网络 涵盖352家门店,包括177家直营店及175家加盟店。于公司直接拥有的177家门店中,84家门店位于一线城 市及73家门店位于新一线城市。公司的直营店与加盟店共覆盖全国100座城市。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 5月22日，截至港股收盘，恒生指数 ...

Financial Performance - Total revenue for 2024 reached RMB2,572 million, representing a year-over-year increase of 19.9%[62]. - Gross profit for the year was RMB1,189,995, with a gross profit margin of 46.3%, up 0.7 percentage points from the previous year[55][62]. - Net profit increased by 9.7% year-over-year to RMB252 million[62]. - Revenue from aesthetic medical services reached RMB928 million, up 9.1% year-over-year[62]. - Revenue from subhealth medical services skyrocketed to RMB201 million, marking a 98.9% year-over-year increase[62]. - Revenue from beauty and wellness services amounted to RMB1,443 million, an increase of 20.9% year-over-year, with a gross profit margin of 40.7%, up 1.1 percentage points[73][75]. - Revenue from the Women's Special Care Center exceeded RMB100 million, increasing over 300% year-over-year, with active members rising by more than 200% year-over-year[101]. - The acquisition of the AI-Powered wellness brand Naturade contributed RMB162 million in revenue since its consolidation in July 2024[122]. - Revenue from beauty and wellness services in direct stores rose by 20.9% from RMB1,080 million in 2023 to RMB1,306 million in 2024[122]. Market Expansion and Acquisitions - The company successfully completed the acquisition of the Guangzhou Naturade brand, expanding its store count to 554 and strengthening its market share in the Greater Bay Area[32]. - The company acquired a 70% stake in Naturade for RMB350 million, marking its entry into the wellness sector[57]. - Naturade contributed RMB287.3 million in revenue to the Group, with 232,860 client visits and 34,252 active members recorded in the second half of 2024[103]. - The company plans to enhance its brand strength through acquisitions or partnerships with upstream skincare brands[35]. - The company will continue to pursue both horizontal and vertical industry consolidation opportunities to expand its market presence[40]. Customer Engagement and Service Innovation - The company upgraded its "Craftsmanship Service" program to better meet customer needs, resulting in a significant market response with 12 monthly sales exceeding 100 million[19][23]. - The successful launch of the LPG BF+ Program highlights the company's ability to respond to growing demands for pain management and body sculpting[19][23]. - The company continues to focus on member value and customer-centric services, addressing the dual challenges faced by women in urban areas[19][23]. - The company is committed to industry innovation, tracking market dynamics to adapt to modern women's evolving needs[19][23]. - The company plans to launch a "Craftsmanship Service" brand upgrade program in 2025, aiming to enhance service quality and customer experience[79]. Operational Efficiency and Technology - The company has invested hundreds of millions of RMB in building digital capabilities over the past five years, transitioning from IT-based systems to data-driven intelligence[36]. - The launch of the CellCare self-developed aesthetic medical business management system in May 2024 significantly enhanced operational efficiency across various business levels[95]. - The company is focused on innovative applications of AI technology in the beauty and health sectors to enhance operational efficiency[39]. - The company plans to deploy AI-powered skin diagnostic devices in all beauty and wellness stores by 2025, enhancing service professionalism and customer experience[80]. - The company is committed to leveraging AI technology in the beauty and health sector to drive innovation and operational decision-making[113]. Shareholder Returns and Financial Strategy - The company plans to distribute no less than 50% of the annual net profit attributable to the parent company's shareholders as dividends over the next three fiscal years[45]. - The company has established a long-term shareholder return mechanism to share growth with shareholders[45]. - The Company's market capitalization surged by 60% in 2024, driven by stellar results and proactive shareholder return strategies[108]. - The Company plans to return at least 50% of annual net profit to shareholders as dividends over the next three fiscal years[111]. Employee and Operational Metrics - The total number of active members increased to 7,552, surging by 80.2% year-over-year, with an active member penetration rate of 6.1%[97]. - The number of client visits at direct stores rose to 1.52 million, a 20.4% increase year-over-year[58]. - Active members in direct stores surged to 137,027, reflecting a 46.3% year-over-year growth[58]. - The number of members in franchised beauty and wellness stores surged to 61,447, a 57.9% increase year-over-year[77][78]. - The total employee welfare expenses for 2024 amounted to RMB1,029 million, an increase from RMB854 million in 2023[194]. - As of December 31, 2024, the Group had a total of 5,609 employees[194].

证券研究报告 | 公司点评 | 医疗美容 ❑ 24 年年报：业绩符合预期，未来 3 年高分红+股权激励彰显发展信心。 24 年业绩符合预期。24 年收入/净利润 25.7/2.5 亿元，同比+19.9%/+9.7%。 24 年 毛利率/净利率 46.3%/9.8%，同比+0.7pp/-0.9pp。销售/管理/研发费用率同比 +0.3pp/+0.2pp/-0.2pp。 公司承诺，自公告日起未来三个完整财年期间将不少于 50%的归母净利用于分 红，也将充分利用管理层股权激励计划，考核指标涵盖未来三年营业收入及利润 提升。 ❑ 基石业务内生稳健增长，医美新客拓展持续，女性特护超预期增长。 24 年收入拆分：生美及保健 56%+医美 36%+亚健康医疗服务 8%。 1） 生美及保健：基石业务内生稳健增长，加码身体护理与智能美养。 24 年收入 14.4 亿（+21%，括号内为同比，下同），毛利率 40.7%（+1.1pcts），具 体来看：①量为主要驱动，全年到店人次/活跃会员人数同增 19.5%/45%。②直营 /加盟收入同增 21%/21%，门店数量分别为 239/276 家。③公司于 24H2 收购奈瑞 儿，新 ...